Searching for clues: can we predict who will respond to lung cancer immunotherapy?
NCT ID NCT03425331
Summary
This study aimed to find biological markers in the blood or tumor that could predict how well patients with advanced non-small cell lung cancer respond to a combination of two immunotherapy drugs (ipilimumab and nivolumab). It was a small, early-phase trial that enrolled only 5 participants before being terminated. The main goal was not primarily to treat patients, but to gather knowledge to help guide future treatment decisions.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02214, United States
Conditions
Explore the condition pages connected to this study.